Company Overview and News

 
Six Sigma Metals eyes copper, silver drill results from Botswana after name change

2017-12-05 proactiveinvestors.com.au
Six Sigma Metals Ltd (ASX:SI6) will start trading on the ASX under its new name and ticker symbol from 11 December, following shareholder approval for its name change from Botswana Metals Ltd.
Upvote Downvote

 
Botswana Metals targets cash boost for cobalt and lithium

2017-08-10 proactiveinvestors.com.au
Botswana Metals Ltd (ASX:BML) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
Upvote Downvote

 
Botswana Metals uncovers additional cobalt drill intercepts

2017-03-02 proactiveinvestors.com.au
Botswana Metals (ASX:BML) has identified cobalt intercepts from historical drilling at the Airstrip Copper prospect located to the west of Maibele in Botswana.
Upvote Downvote

 
Botswana Metals assays reveal lithium, tantalum and tin

2017-02-27 proactiveinvestors.com.au
Botswana Metals (ASX:BML) has received the results of independent laboratory analysis of soil samples from its recent program in north-eastern Botswana.
Upvote Downvote

 
Botswana Metals appoints Steven Groves to the board

2017-02-22 proactiveinvestors.com.au
Groves has a Bachelor of Applied Geology (Honours) and completed a Master’s of Economic Geology at the University of Tasmania.
Upvote Downvote

 
Botswana Metals conducts over-subscribed placement

2017-02-20 proactiveinvestors.com.au
Botswana Metals (ASX:BML) has placed 250 million shares priced at $0.002 to raise $500,000 as part of an over-subscribed share placement.
Upvote Downvote

 
Botswana Metals to pocket funds from share placement

2017-02-08 proactiveinvestors.com.au
Botswana Metals (ASX:BML) has outlined that it intends to place up to 250,000,000 shares at 0.2 cent ($0.002) per share to raise up to $500,000 (before costs) to interested qualifying investors.
Upvote Downvote

 
Botswana Metals to pocket funds from share placement

2017-02-08 proactiveinvestors.com.au
Botswana Metals (ASX:BML) has outlined that it intends to place up to 250,000,000 shares at 0.2 cent ($0.002) per share to raise up to $500,000 (before costs) to interested qualifying investors.
Upvote Downvote

 
Botswana Metal to turn its focus to Dibete and Airstrip

2016-10-13 proactiveinvestors.com.au
Botswana Metals Ltd (ASX:BML) will turn its focus to its Dibete and Airstrip discoveries after its joint venture partner in Botswana, BCL Limited, has entered provisional liquidation.
Upvote Downvote

 
Botswana Metals' hits sulphides in every hole at Takane

2016-10-12 proactiveinvestors.com.au
The final hole, at the Kudu 1 target, intersected three significant sulphide zones, including: 3 metres at 175 metres depth; 0.5 metres at 370 metres; and 1 metre at 382 metres.
Upvote Downvote

 
Botswana Metals in an ASX trading halt

2016-10-11 proactiveinvestors.com.au
BML said that it requested the halt pending clarification of the financial status of BCL Limited. The company considers the clarification to be a material matter given the Farm-in Joint Venture Agreement between the company and BCL. The trading halt will remain in place until the opening of trade on Thursday 13th October 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Botswana Metals Ltd on a sulphide streak in southern Africa

2016-09-22 proactiveinvestors.com.au
Botswana Metals Ltd's (ASX:BML) joint venture partner, BCL Limited, has intersected further sulphides in regional drilling at Takane. The diamond drilling is targeting nickel-copper-cobalt-PGM's, and is located in a known mineralised region. Around 10 kilometres away is the Maibele North project, also a joint venture with BCL, which currently hosts a JORC Resource of 2.38 million tonnes at 0.72% nickel, 0.
Upvote Downvote

 
Botswana Metals Ltd and partner hit sulphides in first hole

2016-09-13 proactiveinvestors.com.au
Botswana Metals Ltd (ASX:BML) has revealed that joint venture partner, BCL Limited, has intersected shallow disseminated sulphide mineralisation in the first hole of a regional drilling program on PL54, known as Takane. Four holes will be drilled at Takane. The area is around 10 kilometres from Maibele North project, which already hosts a JORC Resource of 2.38 million tonnes at 0.72% nickel, 0.21% copper and 0.
Upvote Downvote

 
Botswana Metals Ltd granted licenses prospective for tantalum and lithium

2016-09-09 proactiveinvestors.com.au
Botswana Metals Ltd (ASX:BML) has been granted three new Prospecting Licences to explore for metals in the Limpopo Mobile Zone in Botswana. The licences are prospective for base and precious metals including nickel, copper, gold, silver, tantalum and lithium in pegmatites, and are issued for a first term of three years and can be renewed on 30 September 2019.
Upvote Downvote

 
Botswana Metals Ltd's partner targets new nickel-sulphide province

2016-08-15 proactiveinvestors.com.au
Botswana Metals Ltd's (ASX:BML) joint venture partner, the government-owned BCL Limited, today will start the first deep diamond hole targeting nickel-copper-cobalt-PGM's at East Takane. The area is around 10 kilometres from Maibele North project, which already hosts a JORC Resource of 2.38 million tonnes at 0.72% nickel, 0.21% copper and 0.63g/t of PGE, plus gold. The resource is expected to grow in the near-term.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...